Supplementary References


S51. Group PDMEDC. Long-term effectiveness of dopamine agonists and monoamine oxidase B inhibitors compared with levodopa as initial treatment for Parkinson's disease (PD MED): a large, open-label, pragmatic randomised trial. Lancet 2014;384(9949):1196-205. doi:10.1016/S0140-6736(14)60683-8


S63. NICE TNIfHaCE. Parkinson’s disease in adults. 2019

S64. Kasemsuk C, Oyama G, Hattori N. Management of impulse control disorders with deep brain stimulation: A double-edged sword. *Journal of the Neurological Sciences* 2017;374((Kasemsuk C.; Oyama G., g_oyama@juntendo.ac.jp; Hattori N.) Department of Neurology, Juntendo University, Faculty of Medicine, Tokyo, Japan):63-68. doi: 10.1016/j.jns.2017.01.019


S71. Krishnamoorthy S, Rajan R, Banerjee M, et al. Dopamine D3 receptor Ser9Gly variant is associated with impulse control disorders in Parkinson’s disease patients. *Parkinsonism Relat Disord* 2016;30((Krishnamoorthy S., soumyamoorthy.k@gmail.com; Rajan R., roops84@gmail.com; Kumar H., hardeep@sctimst.ac.in; Sarma G., sarmasg24@yahoo.com; Krishnan S., drsyam@sctimst.ac.in; Kishore A., asha@sctimst.ac.in) Comprehensive Care Centre
for Movement Disorders, Department of Neurology, Sree Chitra Tirunal Institute for Medical Sciences and Technology, India):13-17. doi: 10.1016/j.parkreldis.2016.06.005


